CEN Biotech (CEN Biotech) Debt-to-Equity : -1.94 (As of Mar. 2023)

View and export this data going back to 2016. Start your Free Trial

What is CEN Biotech Debt-to-Equity?

CEN Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $5.05 Mil. CEN Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.13 Mil. CEN Biotech's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $-2.67 Mil. CEN Biotech's debt to equity for the quarter that ended in Mar. 2023 was -1.94.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CEN Biotech's Debt-to-Equity or its related term are showing as below:

CENBF's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.29
* Ranked among companies with meaningful Debt-to-Equity only.

CEN Biotech Debt-to-Equity Historical Data

The historical data trend for CEN Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEN Biotech Debt-to-Equity Chart

CEN Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

-0.90

-0.80

-1.14

-3.34

-2.28

CEN Biotech Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Equity	Get a 7-Day Free Trial															-2.89	-3.01	-2.67	-2.28	-1.94

Competitive Comparison of CEN Biotech's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, CEN Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CEN Biotech's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CEN Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CEN Biotech's Debt-to-Equity falls into.

CEN Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CEN Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.051	+	0.177)	/	-2.291
	=	-2.28

CEN Biotech's Debt to Equity Ratio for the quarter that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.052	+	0.131)	/	-2.672
	=	-1.94

CEN Biotech (OTCPK:CENBF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CEN Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CEN Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CEN Biotech (CEN Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CEN Biotech Inc (OTCPK:CENBF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3295 Quality Way, Suite 300, Windsor, ON, CAN, N8T 3R9

Website

CEN Biotech Inc is an early-stage Canadian biopharmaceutical company. The Company grows, sells, and delivers pharmaceutical-grade medical marijuana to patients.

Executives

Lawrence Lehoux	director, officer: Chief Technology Officer	11879 SOLOMAN ST, WINDSOR A6 N8P 1P1
Jeffery Allen Thomas	director	23772 WEST ROAD #152, BROWNSTOWN TOWNSHIP MI 48183
Rick Leigh Purdy	director	9 ELAINE STREET, ST. ALBERT A0 T8N7R6
Usamakh Saadikh	director	3 DRUDBGY NARODOV SQUARE, KYIV 2H 04210
Joseph A. Byrne	director, officer: Chief Executive Officer	6 CAMERON SIDE ROAD EAST, ESSEX A6 N8M 2X5
Alex Tarrabain	director	18908 89 AVENUE, EDMONTON A0 T5T 6B7
Donald Strilchuck	director	352 RIDEAU PL, TECUMSEH A6 N8N 3N9
Richard Boswell	director, 10 percent owner, officer: CFO Senior Executive VP	2408 EASTERN AVE., ROCHESTER HILLS MI 48307
Ameen Ferris	director	30 AYRSHIRE COURT, BRAMPTON A6 L6Z 0G6
Brian Payne	director, officer: Vice President	1027 HUNTINGTON BLVD, BELLE RIVER A6 N0R 1A0
Aubrey De Lavenu Harold Andre	director	APT 627 VALE DO LOBO, ALMANCIL S1 8135-034
Bahige B. Chaaban	director, 10 percent owner, officer: Chief Executive Officer	888 OLD TECUMSAH RD., BELLE RIVER A6 N0R 1A0

CEN Biotech (CEN Biotech) Headlines

From GuruFocus

CEN Biotech Inc. Announces Planned Strategic Expansion of Business and Closing of Clear Com Media Inc. Acquisition

By ACCESSWIRE ACCESSWIRE • 07-13-2021

CEN Biotech Inc. Announces Word Presto Partner Program

By ACCESSWIRE ACCESSWIRE • 11-08-2022